Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) covers events occurring on February 7, 2018, for Citius Pharmaceuticals, Inc., a Nevada corporation. The filing details the results of the 2018 Annual Meeting of Stockholders, amendments to corporate Bylaws, and final determinations of executive compensation for fiscal year 2017.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation adjustments:
- CEO Myron Holubiak: Final 2017 bonus determined at $186,750 (previously accrued at $225,000). Total 2017 compensation revised to $655,864.
- CFO Jaime Bartushak: Final 2017 bonus determined at $83,000 (previously accrued at $100,000). Total 2017 compensation revised to $438,846.
Material Changes Versus Prior Period
The primary material change is the reduction in accrued executive bonuses for fiscal 2017. The Board determined that the actual attainment of goals resulted in lower payouts than the 100% maximum amounts previously reserved and reported in the December 13, 2017 proxy statement. No other changes to executive compensation were reported.
Corporate Governance and Outlook
Bylaw Amendments: Effective February 7, 2018, the Board amended the Bylaws to allow stockholder proxy access for director nominations. Stockholders (or groups of up to 20) holding at least 3% of outstanding shares for three years may nominate the greater of two individuals or 20% of the board.
Annual Meeting Results:
- Director Elections: All seven nominees were elected with significant "For" votes (approx. 4.7 million each) and minimal "Withheld" votes.
- Auditor Ratification: Wolf & Company, P.C. was ratified as the independent auditor for the fiscal year ending September 30, 2018.
- Stock Incentive Plan: Stockholders approved the 2018 Omnibus Stock Incentive Plan.
Risks and Contingencies: The filing does not disclose new risks or contingencies beyond standard governance updates.
Investor Verification Checklist
- Verify the impact of the reduced executive bonuses on the company's accrued liabilities and net income for fiscal 2017.
- Review the attached Amended and Restated Bylaws (Exhibit 3.1) to understand the specific thresholds for proxy access.
- Confirm the terms of the newly approved 2018 Omnibus Stock Incentive Plan to assess potential future dilution.
- Check subsequent filings for the company's financial performance for the fiscal year ending September 30, 2018, as no financial results were included in this report.